Please login to the form below
allergy
This page shows the latest allergy news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), evaluated a 4mg dose of Olumiant (baricitinib) given alongside remdesivir versus remdesivir alone
Latest news
-
Nestlé is set to acquire Aimmune in deal worth $2.6bn
the biopharmaceutical company’s Palforzia became the first peanut allergy drug to be cleared for use in the US. ... The FDA estimates that only one in five children diagnosed with the allergy eventually outgrow the condition.
-
Moderna’s COVID-19 vaccine shows promise in older adults
The clinical development of mRNA-1273 is being carried out in collaboration with the US National Institute of Allergy and Infectious Diseases, with Moderna having previously been selected to take part
-
FDA grants emergency approval for blood plasma treatments for COVID-19
Earlier this month, top federal health officials in the US, including National Institute of Allergy and Infectious Disease director Antony Fauci and National Institutes of Health director Francis Collins, attempted to
-
Roche, Regeneron partner on COVID-19 antibody cocktail
19. In July, Regeneron advanced the antibody cocktail, REGN-COV2, into a phase 3 trial being jointly run by the US National Institute of Allergy and Infectious Diseases (NIAID).
-
Speed kills
I would not be surprised if we go up to 100, 000 a day if this does not turn around,” Dr Anthony Fauci, Director of the National Institute of Allergy and
More from news
Approximately 16 fully matching, plus 203 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
I don’t think the ongoing trials will tell us a lot,” said H Clifford Lane, clinical director at the National Institutes of Allergy and Infectious Diseases (NIAID).
-
Cortellis Drugs to Watch in 2020 report
This year’s list also highlights three first-in class medicines compared with last year’s list, which contained only one first-in-class medicine, peanut allergy vaccine Palforzia.
-
The long and winding road to asthma breakthroughs
The high unmet need was reinforced by a report issued in October by the European Federation of Allergy and Airways Diseases’ Patients’ Associations (EFA), which revealed there were 30 million children
-
Integrating patient reported outcomes into clinical trials
Aimmune Therapeutics prepared for commercialisation by using two PRO scales to show the effect of its peanut allergy drug on people’s emotions and social lives.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.
More from intelligence
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest appointments
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Before AstraZeneca, she worked for GlaxoSmithKline for four years in a number of roles, including therapy specialist for its allergy portfolio.
-
ALK-Abello appoints Søren Jelert as CFO
He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... to become a truly global allergy company.”.
-
Cytovation expands management team
Grego is currently chief executive officer of Spire Bioventures, a global healthcare consultancy and mentoring service, and has previously held a number of management positions at Spanish allergy specialist Laboratorios LETI.
-
Lars Dreiøe joins Sobi in senior quality and compliance role
He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.
-
ARC names chairman and member of the board
ARC is a privately held biopharma company developing desensitisation treatments for food allergies. ... Iwicki said: “ARC is working to address a very compelling therapeutic area and provide an option to those dealing with food allergies.
More from appointments
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest from PMHub
-
Wilmington Healthcare appoints new consultants
for its allergy portfolio.
-
Corporate event food. How to get it right
Vegetarian. Vegan. Gluten-free. Peanut allergies. Lactose intolerant. Diabetic. Kosher. Halal. To keep everyone happy, be sure to ask your delegates if they have any dietary requirements ASAP.
-
Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments
Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment. ... This is not an isolated incident, but a constant fear and source of anxiety for allergy sufferers all over the
-
Atopic Dermatitis — Going Beyond the Pill
The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies.
-
Barber shops provide a short cut to BP reduction
Allergy testing in flower shops? Why not? All it requires is localised expertise, and a government that is keen to devolve the complexity and cost of healthcare, which the NHS is
More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Lilly starts large-scale trial of tirzepatide in diabetic heart disease
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
PMHub
Spirit
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
